SFRVN
Sf-RVN™ Insect Cell Line
Synonym(s):
Sf9 rhabdovirus-negative (Sf-RVN™) Insect Cell Line
Select a Size
+351 213 164 031or
This item is not able to be purchased as a guest user. For further information, please contact us at .Select a Size
About This Item
+351 213 164 031or
This item is not able to be purchased as a guest user. For further information, please contact us at .Recommended Products
description
Sf9 rhabdovirus-negative (Sf-RVN™) Insect Cell Line
solubility
DMSO: 10%
shipped in
liquid nitrogen
storage temp.
−196°C
General description
Cell Line Origin
Sf-RVN™ is an insect cell line originally derived from ovarian tissue of Spodoptera frugiperda (Sf) pupae. The parental line, IPLB-SF-21 (renamed IPLB-SF-21 AE after adaptation into TC-100 medium), was established by J. Vaughn at the Insect Pathology Beltsville in Maryland, USA in the late 1960s. A subclone, designated Sf9, was established in 1983 by G. Smith and C. Cherry. Sf-RVN™ was isolated from Sf9 by GlycoBac, LLC.
Physical form
Other Notes
Legal Information
related product
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
EU REACH Annex XVII (Restriction List)
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.
To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.
The current status and future manufacturing of AAV-based gene therapies is discussed in this podcast transcript, including how to streamline large-scale manufacturing.
Upstream gene therapy optimization maximizes viral vector titers; partner with technology experts for HEK293, HEK293T, and Sf9 cell solutions.
Related Content
A transfection-based solution to viral vector production using a suspension cell line, chemically defined medium, and a process with proven performance at scale.
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service